Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Neutralizing Antibody Responses in COVID-19 Convalescent Sera.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Lee, William T (); Girardin, Roxanne C (); Dupuis, Alan P (); Kulas, Karen E (); Payne, Anne F (); Wong, Susan J (); Arinsburg, Suzanne (); Nguyen, Freddy T (); Mendu, Damodara Rao (); Firpo-Betancourt, Adolfo (); Jhang, Jeffrey (); Wajnberg, Ania (); Krammer, Florian (); Cordon-Cardo, Carlos (); Amler, Sherlita (); Montecalvo, Marisa (); Hutton, Brad (); Taylor, Jill (); McDonough, Kathleen A ()
- Source:
Journal of Infectious Diseases. Jan2021, Vol. 223 Issue 1, p47-55. 9p.
- Additional Information
- Subject Terms:
- Subject Terms:
- Abstract:
Passive transfer of antibodies from COVID-19 convalescent patients is being used as an experimental treatment for eligible patients with SARS-CoV-2 infections. The United States Food and Drug Administration's (FDA) guidelines for convalescent plasma initially recommended target antibody titers of 160. We evaluated SARS-CoV-2 neutralizing antibodies in sera from recovered COVID-19 patients using plaque reduction neutralization tests (PRNT) at moderate (PRNT50) and high (PRNT90) stringency thresholds. We found that neutralizing activity significantly increased with time post symptom onset (PSO), reaching a peak at 31-35 days PSO. At this point, the number of sera having neutralizing titers of at least 160 was approximately 93% (PRNT50) and approximately 54% (PRNT90). Sera with high SARS-CoV-2 antibody levels (>960 enzyme-linked immunosorbent assay titers) showed maximal activity, but not all high-titer sera contained neutralizing antibody at FDA recommended levels, particularly at high stringency. These results underscore the value of serum characterization for neutralization activity. [ABSTRACT FROM AUTHOR]
